At the recent AAAAI/WAO meeting, Blueprint Medicines Corp. presented the in vitro and in vivo characterization of BLU-808, a selective inhibitor of wild-type KIT, a transmembrane receptor tyrosine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback